ORIC
ORIC Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
9.24
close · 2026-10-30
value
68
cheaper than peers68
quality
75
stronger fundamentals75
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -21.2% | 63 |
| cash flow yield, latest year | -11.7% | 62 |
| earnings yield, 3 years ago | -24.4% | 61 |
| earnings yield, latest year | -15.9% | 60 |
| cash flow yield, 2 years ago | -9.0% | 60 |
| cash flow yield, 3 years ago | -8.1% | 60 |
| cash flow yield, 1 year ago | -11.9% | 59 |
| earnings yield, 1 year ago | -19.8% | 58 |
| price to book | 2.51× | 47 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -39.8% | 74 |
| debt to equity | 1.6% | 64 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $958M |
| free cash flow | -$68.8M |
| employees | 111 |
| first trade | 2020-04-24 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.47 | -1.83 | -1.96 | -2.25 | not reported |
| free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | not reported |
| net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | $0 | -$5.0M | $0 |